Oppenheimer Maintains Outperform on Syros Pharmaceuticals, Lowers Price Target to $3
Oppenheimer analyst Mark Breidenbach maintains Syros Pharmaceuticals (NASDAQ:SYRS) with a Outperform and lowers the price target from $9 to $3.
Syros Pharmaceuticals Granted Canadian Patent Titled ‘HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES (E.G., CANCERS, LEUKEMIA, AUTOIMMUNE DISEASES)’
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2927917/summary.html
Syros Pharmaceuticals Q2 EPS $(0.54) Down From $(0.36) YoY, Sales $6.30M Beat $4.57M Estimate
Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.54) per share. This is a 50 percent decrease over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday’s Mid-Day Session
Gainers
InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday.
Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application…
HC Wainwright & Co. Maintains Buy on Syros Pharmaceuticals, Lowers Price Target to $6
HC Wainwright & Co. analyst Andrew Fein maintains Syros Pharmaceuticals (NASDAQ:SYRS) with a Buy and lowers the price target from $10 to $6.
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
Passage Bio (NASDAQ:PASG) shares moved upwards by 7.7% to $2.66 during Friday's after-market session. The market value of their outstanding shares is at $144.4 million.
HC Wainwright & Co. Maintains Buy on Syros Pharmaceuticals, Lowers Price Target to $10
HC Wainwright & Co. analyst Andrew Fein maintains Syros Pharmaceuticals (NASDAQ:SYRS) with a Buy and lowers the price target from $15 to $10.